KRP-AM1977X Phase III Comparative Study (Community acquired pneumonia)

KRP-AM1977X PhaseIII Clinical Study-Double blind comparative study for the patients with community acquired pneumonia-

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222860

Enrollment

250

Registered

2015-05-25

Start date

2015-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community acquired pneumonia (including Mycoplasma pneumonia, Chlamydia Pneumonia, or Legionella pneumonia)

Interventions

investigational material(s) Generic name etc : KRP-AM1977X Tablet INN of investigational material : lascufloxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Community acquired pneumonia with clear infection symptoms

Exclusion criteria

Exclusion criteria: Pneumonia patient except the community-acquired pneumonia Patient with serious functional disorder that would unsuitable for the study Patient showing the tendency to improve pneumonia symptoms by other agents etc.

Design outcomes

Primary

Measure	Time frame
efficacy Clinical efficacy at test of cure Assessment of clinical response by comparing the clinical findings and chest X-ray or CT results.	—

Secondary

Measure	Time frame
efficacy Clinical efficacy at end of treatment, etc. Assessment of clinical response by comparing the clinical findings and chest X-ray or CT results.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026